Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
6.7
2.70%
60%
—
275.30%
Every year
—
5 Years
Score6.7
Net Growth2.70%
Net Trend60%
Net Income Consistency—
Rev Growth275.30%
Rev TrendEvery year
Revenue Consistency—
Halozyme Therapeutics Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 267M to $ 1.39B and net income grew from $ 129M to $ 316M. Revenue increased in every one of those 5 years; net income in 3.
Between 2015 and 2025, revenue grew from $ 135M to $ 1.39B and net income went from -$ 32M to $ 316M. Revenue increased in 9 of those 10 years; net income in 7.
Halozyme Therapeutics Inc currently holds a 20-year HDB Score of 6.4 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 101.79 | — |
1 Year2025-08-12 | $ 64.04 | 58.95% |
5 Years2021-08-12 | $ 41.59 | 144.75% |
10 Years2016-08-12 | $ 10.25 | 9x |
20 Years2006-08-11 | $ 2.30 | 44x |
All Time2004-03-16 | $ 4.25 | 23x |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | 20 Years2006-08-11 | All Time2004-03-16 |
|---|---|---|---|---|---|---|
| Price | $ 101.79 | $ 64.04 | $ 41.59 | $ 10.25 | $ 2.30 | $ 4.25 |
| Return | — | 58.95% | 144.75% | 9x | 44x | 23x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 1.66B | $ 413M | $ 231M |
| 2025 | $ 1.39B | $ 316M | $ 142M |
| 2024 | $ 1.01B | $ 444M | $ 596M |
| 2023 | $ 829M | $ 281M | $ 336M |
| 2022 | $ 660M | $ 202M | $ 362M |
| 2021 | $ 443M | $ 402M | $ 740M |
| 2020 | $ 267M | $ 129M | $ 368M |
| 2019 | $ 195M | -$ 72M | $ 421M |
| 2018 | $ 151M | -$ 80M | $ 354M |
| 2017 | $ 316M | $ 62M | $ 469M |
| 2016 | $ 146M | -$ 103M | $ 204M |
| 2015 | $ 135M | -$ 32M | $ 108M |
| 2014 | $ 75M | -$ 68M | $ 135M |
| 2013 | $ 54M | -$ 83M | $ 71M |
| 2012 | $ 42M | -$ 53M | $ 99M |
| 2011 | $ 56M | -$ 19M | $ 52M |
| 2010 | $ 13M | -$ 53M | $ 83M |
| 2009 | $ 13M | -$ 58M | $ 67M |
| 2008 | $ 8M | -$ 48M | $ 63M |
| 2007 | $ 3M | -$ 23M | $ 97M |
| 2006 | $ 981.75K | -$ 14M | $ 44M |
| 2005 | $ 127.21K | -$ 13M | $ 19M |
| IPO2004 | -$ 9M | $ 16M |
Explore beyond HALO
You're looking at Halozyme Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
